Total Endovenous Laser Ablation Multicenter (TOTEM) trial: Early results.
J Vasc Surg Venous Lymphat DisordJun 13, 2026 (epub)
Luca Palombi, Jan Szczepański, Fabio Martinelli et al.
✦ AI-curated · Sources linked
In 30 seconds
The TOTEM trial evaluated the safety and efficacy of total endovenous laser ablation (TEVLA) in a multicenter cohort of 153 patients with CEAP C2-C6. This prospective nonrandomized study found an occlusion rate of 99.3% at 7 days and 98.3% at 6 months, indicating high effectiveness of the procedure.
Key findings
- Occlusion rate was 99.3% at 7 days and 98.3% at 6 months.
- Mean revised Venous Clinical Severity Score improved by -3.24 at 1 month (P < .001).
- Minor complications included hyperpigmentation (5.9%) and paresthesia (2.6%).
Why it matters
The findings suggest that TEVLA is a highly effective treatment option for patients with venous insufficiency, with minimal complications. Understanding its efficacy can help clinicians make informed decisions regarding treatment strategies.